Lisocabtagene Maraleucel

Preferred Label : Lisocabtagene Maraleucel;

NCIt synonyms : Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017; Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8 and CD4 T-lymphocytes JCAR017; Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017; Liso-cel;

NCIt definition : A preparation of a defined ratio of CD4 and CD8 autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.;

UNII : 7K2YOJ14X0;

Drug name : Breyanzi;

Molecule name : JCAR-017; JCAR 017;

NCI Metathesaurus CUI : CL504006;

Codes from synonyms : 21215;

Details

Origin ID

C125192;

UMLS CUI

C4086001;

Currated CISMeF NLP mapping
- Lisocabtagene maraleucel [SMS substance]
- Lisocabtagene maraleucel (substance) [SNOMED CT concept]
Semantic type(s)
- Cell [UMLS semantic type]
UMLS correspondences (same concept)
- Lisocabtagene maraleucel (substance) [SNOMED CT concept]
- Product containing lisocabtagene maraleucel (medicinal product) [SNOMED CT concept]
- lisocabtagene maraleucel [ATC Code]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD19 [NCIt concept]
is_component_of_chemotherapy_regimen
- Lisocabtagene Maraleucel Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients